Price
No data yet.
Social Signal Score
Analyst Ratings
17 analystsRevenue
$41.75M-9.74%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- James Barr IV
- Sector
- Consumer Cyclical
- Industry
- Leisure
- Employees
- 411
- Beta
- 1.59
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 2.05
Financials
Revenue
$41.75M-9.7%Net Income
$-4.92M-455.8%EBITDA
$1.64M+22.6%Free Cash Flow
$-3.54MEPS (diluted)
$-0.15-475.0%Shares Outstanding (diluted)
32.35M+2.8%Operating Expenses
$18.74MCash & Debt
$17.33MReturn of Capital
$0.00Revenue by Segment (annual)
$286.77MDividend per Share
$0.10Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2023 | $286.77M | $-107.49M | $-3.40 |
| 2022 | $589.53M | $-22.20M | $-0.72 |
| 2020 | $552.56M | $59.85M | $1.99 |
| 2019 | $309.29M | $-92.80M | $-3.13 |
| 2018 | $396.75M | $14.66M | $0.49 |
| 2017 | $406.18M | $26.27M | $0.86 |
| 2016 | $406.04M | $34.18M | $1.10 |
| 2015 | $335.76M | $26.60M | $0.85 |
| 2014 | $274.45M | $18.80M | $0.60 |
| 2013 | $218.80M | $47.95M | $1.54 |
| 2012 | $193.93M | $16.88M | $0.55 |
| 2011 | $180.41M | $1.42M | $0.05 |
| 2010 | $168.45M | $-22.84M | $-0.74 |
| 2009 | $189.26M | $-53.30M | $-1.74 |
Valuation
NLShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
75+150.00%Social Signal Score
Mentions (6)
- Newsseekingalpha.com·24d ago·Positive
Nautilus Biotechnology: Bullish On Voyager's Upcoming Launch NAUT is extending Voyager from tau into oncology, which I think will give it more applications for its targeted proteoform platform. NAUT also has research collaborations and SEEDS participation. In my view, this corroborates that there's real scientific interest in their platform. Management's runway projection should be enough to reach their planned launch of Voyager instruments and initial assay kits.
View source ↗ - Newsglobenewswire.com·26d ago·Neutral
Nautilus to Measure Proteoforms Driving Alzheimer's Disease and Cancer in ARPA-H-Funded SEEDS Consortium Nautilus expects to receive up to $6 million to bring its Voyager™ Platform to a multidisciplinary team integrating protein science, AI, and computational modeling to develop new diagnostics and therapeutics Nautilus expects to receive up to $6 million to bring its Voyager™ Platform to a multidisciplinary team integrating protein science, AI, and computational modeling to develop new diagnost
View source ↗ - Newsglobenewswire.com·26d ago·Neutral
Nautilus Biotechnology Reports Third Quarter 2026 Financial Results SEATTLE, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2026.
View source ↗ - Newsthenewswire.com·45d ago·Negative
Red Canyon Initiates First Diamond Drill Program on its Nautilus Copper-Gold Target Vancouver, British Columbia - TheNewswire - October 8, 2026: Red Canyon Resources Ltd. (“Red Canyon” or the “Company”) (CSE: REDC | OTCQB: REDRF | Frankfurt: I9I) is pleased to announce that it has initiated a first-pass diamond drill program at its 100% owned Nautilus copper-gold target within the Osiris Project in central British Columbia. The program will test priority targets defined by the integration of pro
View source ↗ - Newsglobenewswire.com·79d ago·Negative
Nature Methods Publication Reveals Deep Insights into Functional Biology through First-of-its-Kind Quantification of Tau Proteoforms First large-scale, single-molecule analysis of the tau proteoform landscape reveals unique disease-associated modifications, a new source of potential biomarkers and drug targets, and a method Nautilus is now extending across disease areas First large-scale, single-molecule analysis of the tau proteoform landscape reveals unique disease-associated modifications, a
View source ↗ - Newsbusinesswire.com·82d ago·Negative
Guardian Pharmacy Services Acquires Assets of Tennessee-Based Nautilus Pharmacy ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. (NYSE: GRDN) has acquired assets from Tennessee-based Nautilus Pharmacy.
View source ↗
Earnings
Typical surprise -7.7% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 8$-0.48 vs $-0.29miss
- Wed, Aug 9$-0.33 vs $-0.50beat
- Tue, May 23$-0.56 vs $-0.52miss
- Thu, Feb 9$-0.35 vs $-0.30miss
- Wed, Nov 9$-0.48 vs $-0.51beat
Estimates and results for NLS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NLS officers and directors.
No open-market trades in the recent filings. All 100 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
100 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in NLS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
